



Jonathan Foulds
Candidate – President Elect

Jonathan Foulds, PhD. is a Professor of Public Health Sciences at Penn State University, College of Medicine. He trained as a clinical psychologist at the University of Glasgow, and obtained his PhD at the Institute of Psychiatry, University of London. He has spent most of his career developing and evaluating methods to help smokers beat their addiction to tobacco. He was a founding member and Vice President of the Association for the Treatment of Tobacco Use and Dependence (ATTUD). He has published over 190 scientific papers and book chapters on tobacco and nicotine and has been invited to speak on smoking cessation in over 15 countries. He is Co-director of the Penn State Center for Research on Tobacco and Health. Together with Dr Jill Williams, he wrote the 2025 book, “Treating Addiction to Tobacco and Nicotine Products” published by the American Psychiatric Association.

Dr Foulds has been a member of SRNT for over 20 years and has attended almost all the SRNT annual conferences this century, as well as the SRNT-Europe conferences in London, Madrid, Santiago de Compostela and Oslo. He has served on the SRNT website committee and co-chaired the SRNT Policy Network 2013-15. At that time he drafted the SRNT position statement on menthol cigarettes for submission to the U.S. FDA. He has given oral presentations on behalf of SRNT to U.S. FDA on long term use of nicotine medications and on regulation of medicines for smoking cessation. He has been a long-time reviewer for the society’s journal (NTR) and has been a co-author of 18 papers published in NTR.

Over the past 15 years his own research has focused more on tobacco regulatory science, including studies of reduced-nicotine cigarettes, electronic cigarettes and nicotine pouches. His aim is to help SRNT continue to be the world’s leading scientific society providing a forum for the publication, presentation and respectful discussion of nicotine and tobacco research.

2025/2026 SRNT Disclosure of Competing Interest Form

Name: Jonathan Foulds PhD Date: November 5, 2025

Please provide the **name of all sources of funding or salary support** from any of the following sources **during the past 5 years**. Please write the name of the source in the box that best represents the type of funding received or the nature of your relationship. If you have no relationship in a given category, check the “No relationship” box.

Type of Relationship	Commercial Tobacco Product Manufacturer	Nicotine Product (vape, chewable, etc.) Manufacturer	Pharmaceutical Company	Gov’t Agency	Private Foundation	Advocacy or Public Health Organization	Any Other
No Relationship					X		
Full or Part Time Employment							X My full-time salary is paid by Penn State College of Medicine.
Consultancy ¹			X Paid consulting for Johnson & Johnson, on clinical trial design				X Paid consulting for other universities on grant peer review.

Honoraria ²				X Received payment from NIH for acting as a grant reviewer.		X Conducted paid trainings for healthcare organizations and universities: MaineHealth, University of Southern California, Florida State University	
------------------------	--	--	--	--	--	---	--

Research grant, or contract				X I am a Principal Investigat or and Co- Investigat or on research grants funded by NIH (NIDA and NCI)		X I received a research grant and access to data from their own records from a national Quitline provider (National Jewish Health)	
Ownership of stock shares or equity ³							

Paid expert testimony							
Patent							
Receipt of product or database for research	X Recipient of ZYN and placebo pouches for RCT, paid for from NIH grant (Phillip Morris International, via their subsidiary Swedish Match). Recipient of electronic cigarettes (NIDA Standardized Research Electronic Cigarette, from NJOY, currently	X Recipient of research electronic cigarettes and placebo, for an RCT funded by an NIH grant (Juul, currently an independent nicotine product manufacturer but they have also been part-owned by a tobacco company in the past) funded from an NIH grant					

	owned by Altria), funded from an NIH grant Received Spectrum reduced nicotine Research Cigarettes at no cost from NIH NIDA, who purchased them under contract with a cigarette manufacturer						
Indirect funding of any sort							

Other relationship (specify on following page)						I have agreed to provide presentations at some events without an honorarium but in which the organization provides travel expenses. E.g 2024 Nicotine and Tobacco Science Conference, Medical University of South Carolina, Charleston Oct 29, 2024.	I have co authored a 2025 book on Treating Addiction to Tobacco and Nicotine Products, published by American Psychiatric Association Publishing, and receive royalties from sales of the book.
--	--	--	--	--	--	---	---

¹Consultancy is defined a payment from an organization for providing advice or expertise on a topic.

²Honoraria are payments for making a presentation to scientists, clinicians, administrators, the press, etc.

³Does not include ownership of mutual funds that may include stocks in these industries.

For every funding source listed in the table on page 1, specify the nature of the relationship and ANY potential conflict:

For each of the tobacco companies or non-therapeutic nicotine companies providing research products (electronic cigarettes, placebos, nicotine pouches) for NIH-funded clinical trials, the funds to purchase these products are provided by grants from the National Institute on Drug Abuse (NIH-NIDA), and my university pays for these products at the market rate in response to an invoice from the company. So the relationship is no more than they agree to sell us product and a research grant pays for it on invoice, as approved by NIH and an IRB. In the case of the Spectrum research cigarettes, these were provided at no cost by NIDA, in order to facilitate research relevant to a potential Reduced Nicotine Standard for cigarettes as proposed by FDA Center for Tobacco Products. There is no conflict of interest.

Regarding my consulting for Johnson and Johnson on clinical trial design, they paid for my time and expertise at the market rate (over 3 years ago) and that was the end of it. I see no conflict of interest but report this to my University Conflict of Interest Committee, who initiate CoI management plans as required.

Regarding the book that was recently published by APA Publishing, I do not see how that presents a conflict of interest. Similarly, the acceptance of reasonable travel expenses to present at educational meetings/conferences (at Medical University of South Carolina) does not present a conflict of interest.

Of all the funding sources listed on table 1, the one that provides the largest benefit to me, personally (greater than all the others combined), is grant funding from NIH. This not only enables me to do my job effectively, it increases my chances of career progression and incentive bonuses from my university employer. So my primary conflict of interest is in relation to this funding source, and consideration that it could be jeopardized by speaking or writing publicly in a manner that could potentially conflict with a potential funding federal agency. E.g. publishing a paper that criticizes the way federal agencies managed the EVALI outbreak.

Please list future funding sources that are either in process or approved but not yet in force:

Currently finalizing a Data Use Agreement with The Truth Initiative in which they will share data and we will analyze it (no payment involved)

I have agreed to present at the E-Cigarette Summit (London) in December 2025 without an honorarium but in which the organization provides travel expenses. The E-Cigarette Summit (London) is organized by Smooth Events (who do not accept industry payment or sponsorship).